GNE-293
GNE-293 is a potent and selective PI3Kδ inhibitor (IC50 = 4.38 nM). GNE-293 has favorable pharmacokinetic properties. GNE-293 can be used for research of asthma, rheumatoid arthritis, and other inflammatory disorders.
For research use only. We do not sell to patients.
- CAS No.: 1354955-67-1
- Formula: C28H36N8O4S
- Molecular Weight:580.70
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
4.38 nM (PI3Kδ)[1].
Chemical Information
-
CAS No. 1354955-67-1
-
Molecular Weight 580.70
-
Formula C28H36N8O4S
-
SMILES
CC(C)C1=NC(C=CC=C2)=C2N1C3=NC4=C(N=C(OC5CN(C6CCS(CC6)(=O)=O)C5)N4C)C(N7CCOCC7)=N3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)